What are the trends in the global competitiveness of the Indian pharmaceutical industry? Where does this industry stand when compared to global peers on pharmaceutical value-added, productivity, research and development and trade performance? What are the new strategies that Indian...

Multinational companies (MNCs) from emerging markets (EMs) are new and very dynamic actors on the global scene. Starting from the late 1970s a strand of literature flourished on Third World multinationals (Lall, 1983a). More recently, the increasing expansion abroad by multinationals based in...

External referencing (ER) imposes a price cap for pharmaceuticals based on prices of identical products in foreign countries. Suppose a foreign country (F) negotiates prices with a pharmaceutical firm while a home country (H) can either negotiate independently or implement ER based on the...

This paper explains how the current architecture of the pharmaceutical markets has created a misalignment of financial incentives and public health that is a central cause of harmful practices. It explores three possible solutions to address that misalignment: taxes, increased financial...

This study analyses 1400 research projects of the top 20 R&D-spending pharmaceuticals to identify the determinants of successful research projects. We provide clear evidence that externally sourced projects and projects involving biotechnologies perform better than internal projects and chemical...

The study focuses on the manner in which diversification strategy is applied to the pharmaceutical industry. The paper deals with diversification business models, such as the blockbuster model and the generic drugs model. Also, an important trend in the pharmaceutical industry is related to...

Physicians’ generic pharmaceutical adoption involves not only patients’ and insurance payers’ cost, but also their own interests. This study examines this double agency problem for physicians by using Taiwanese data because two of its institutional features: First, patients and physicians...

We have examined all the US patents (444) issued to homegrown Indian pharma and pharma biotech firms. Most (425, 95%) patents are pharma patents not biotech (19). Also, only 11 patents have been cited ten times or more. This data provides one snapshot of the biotech industry in India today. It...

Patents are important for biotechnology and pharmaceutical companies. In order to remain valid, an issued patent has to be ‘maintained’ by the payment of fees to the patent office at three well-defined times over several years. The article examines whether Indian companies in these sectors...

Technological capabilities of firms and other firm resources have been researched by many researchers to assess their impact on export competitiveness of Indian industries. This study reports the findings of the influence of technological capabilities and firm resources on the export performance...